Adenosine given before primary PCI to reduce no-reflow in STEMI patients.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, single-blinded, randomized study enrolling 1,148 adults with STEMI undergoing primary PCI and randomizing them 1:1 to intracoronary adenosine pre-medication or standard care. The intervention uses weight-independent intracoronary doses (2 mg for left coronary, 1 mg for right, diluted) administered before reperfusion. The primary outcome is incidence of slow flow/no-reflow by TIMI flow grade, with myocardial blush grade as a secondary outcome. Key exclusions include cardiogenic shock, heart block, and known adenosine allergy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All patients with acute STEMI undergoing primary PCI
* Patients of either sex, ≥18 years of age.

Exclusion Criteria:

* STEMI patients with cardiogenic shock at presentation
* Patients with heart block
* Allergy to adenosine
* Patients refuse to give consent for participation

Where it's running

• National Institute of Cardiovascular Diseases
  Karachi, Sindh, Pakistan Recruiting
• National Institute of Cardiovascular Diseases
  Karachi, Sindh, Pakistan Recruiting

Study contacts

• Principal investigator: Muhammad Nauman, FCPS — National Institute of Cardiovascular Diseases
• Study coordinator: Muhammad Nauman Khan, FCPS
• Email: nkhan116@yahoo.com
• Phone: +923453549634

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Administering adrenaline in STEMI patients during PCI to prevent no reflow

  This study tests if giving adrenaline during heart procedures can help STEMI patients avoid complications with blood flow without causing heart rhythm problems.

  Recruiting Phase 3 Ain Shams University · Cairo · NCT06847568

• Evaluating a noninvasive tissue sensor to detect cardiogenic shock earlier in heart patients

  This pilot, noninvasive study tests whether the NIRSense wearable can help detect deterioration in adults with cardiogenic shock risk due to heart attack or heart failure.

  Recruiting NIRSense Inc. · Weston, Florida · NCT07825363

• Brain blood flow changes after successful clot removal in acute ischemic stroke

  This study will use a special MRI blood-oxygenation breathing test to see if it can detect patients with acute ischemic stroke who do not improve after successful clot removal.

  Recruiting University of Zurich · Zurich, Canton of Zurich · NCT07534319

• Subclinical depression in people after a first heart attack (SUBDIMA25)

  This project will test how common mild depressive symptoms are in adults hospitalized for a first heart attack and whether those symptoms relate to biomarkers, heart function, and recovery over the next year.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, Italia · NCT07492537

• Long-term follow-up after Hearticellgram-AMI treatment

  We will follow people who got one dose of Hearticellgram-AMI after a heart attack for up to 60 months to see if the treatment stays safe.

  Recruiting Pharmicell Co., Ltd. · Seoul, Gangnam · NCT07400458

• Long-term remote ischemic preconditioning after a heart attack

  This trial will test whether daily brief arm blood‑flow restriction after a recent heart attack can lower the chance of major heart and brain events over the following year for people treated for acute myocardial infarction.

  Recruiting Henan Institute of Cardiovascular Epidemiology · Zhengzhou, Henan · NCT07181356

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.